AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9096856 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium nicotinic acid supplementation (200 micrograms)
Number of subjects: 19
Study 9096856 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 1912107 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2 mg
Number of subjects: 8
Study 1912107 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 8
Study 1912107 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 8 mg
Number of subjects: 8
Study 1912107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6356324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 6356324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6356324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 29465346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg with methotrexate
Number of subjects: 299
Study 29465346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg with methotrexate
Number of subjects: 299
Study 29465346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (both dosages)
Number of subjects: 299
Study 27344118 — intervention group
Group type: EXPERIMENTAL
Intervention: HHH (chronic cigarette, alcohol, and marijuana use)
Number of subjects: 0
Study 27344118 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD (delayed/late‐starting cigarette, alcohol, and marijuana use)
Number of subjects: 0
Study 27344118 — intervention group
Group type: EXPERIMENTAL
Intervention: LML (low/no smoking, moderate alcohol use, occasional marijuana use)
Number of subjects: 0
Study 27344118 — intervention group
Group type: EXPERIMENTAL
Intervention: HMN (chronic smoking, moderate alcohol use, no marijuana use)
Number of subjects: 0
Study 27344118 — intervention group
Group type: COMPARATOR
Intervention: NON (occasional alcohol use only)
Number of subjects: 0
Study 25826889 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified skull traction surgery (trial group)
Number of subjects: 90
Study 25826889 — intervention group
Group type: COMPARATOR
Intervention: Traditional skull traction surgery (control group)
Number of subjects: 90
Study 25826889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 23248957 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated suture fixation method
Number of subjects: 114
Study 23248957 — intervention group
Group type: COMPARATOR
Intervention: Packaging group (traditional suture-package fixation method)
Number of subjects: 114
Study 23248957 — intervention group
Group type: COMPARATOR
Intervention: Packaging group
Number of subjects: 114
Study 19800061 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (0.25 mg/d on days 1, 2, and 3 of the menstrual cycle)
Number of subjects: 53
Study 19800061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GnRH antagonist supplementation)
Number of subjects: 53
Study 18341675 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase 4 inhibitors
Number of subjects: 0
Study 18341675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16841667 — intervention group
Group type: EXPERIMENTAL
Intervention: Gegen Qinlian Decoction (GQD) combined with insulin treatment
Number of subjects: 30
Study 16841667 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (insulin treatment alone)
Number of subjects: 30
Study 16841667 — intervention group
Group type: EXPERIMENTAL
Intervention: GQD group
Number of subjects: 30
Study 16841667 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 30
Study 12646745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DFNa)
Number of subjects: 200
Study 12646745 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone phosphate (BMS)
Number of subjects: 200
Study 11813767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase mammography compliance
Number of subjects: 817
Study 9121664 — intervention group
Group type: EXPERIMENTAL
Intervention: 14G intravenous catheter
Number of subjects: 114
Study 9121664 — intervention group
Group type: COMPARATOR
Intervention: 16G intravenous catheter
Number of subjects: 114
Study 7688829 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (375 mg p.o. daily)
Number of subjects: 54
Study 7688829 — intervention group
Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA) (100 mg p.o. daily)
Number of subjects: 54
Study 7688829 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 54
Study 7688829 — intervention group
Group type: COMPARATOR
Intervention: CMA
Number of subjects: 54
Study 7688829 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide and CMA
Number of subjects: 54
Study 2953226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (0.2 mg)
Number of subjects: 12
Study 2953226 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicardipine)
Number of subjects: 12
Study 31175197 — intervention group
Group type: EXPERIMENTAL
Intervention: Power estimations of non-primary outcomes
Number of subjects: 0
Study 31175197 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic use of power estimations
Number of subjects: 0
Study 30463608 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care with financial incentives (up to $550) for participating in the New York Smoker's Quitline, using nicotine replacement therapy, and achieving biochemically confirmed smoking cessation at 2 months and 6 months.
Number of subjects: 182
Study 30463608 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care without financial incentives (usual smoking cessation care).
Number of subjects: 182
Study 26306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration 24 hours after chemotherapy (cohort A)
Number of subjects: 41
Study 26306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration 72 hours after chemotherapy (cohort B)
Number of subjects: 41
Study 26306520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration 96 hours after chemotherapy (cohort C)
Number of subjects: 41
Study 24865694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CTPA (80 kVp, 75 ml CM)
Number of subjects: 501
Study 24865694 — intervention group
Group type: COMPARATOR
Intervention: Normal-dose CTPA (100 kVp, 100 ml CM)
Number of subjects: 501
Study 22418088 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg choline/d
Number of subjects: 47
Study 22418088 — intervention group
Group type: EXPERIMENTAL
Intervention: 930 mg choline/d
Number of subjects: 47
Study 22418088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal choline intake
Number of subjects: 47
Study 22418088 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 47
Study 20422401 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery total knee arthroplasty (CAS-TKA)
Number of subjects: 60
Study 20422401 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (TKA)
Number of subjects: 60
Study 17910601 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour mid-day nap
Number of subjects: 0
Study 17910601 — intervention group
Group type: COMPARATOR
Intervention: Melatonin
Number of subjects: 0
Study 17910601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17910601 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness
Number of subjects: 0
Study 16492649 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention combining cognitive behavioral strategies and a self-help manual
Number of subjects: 244
Study 16492649 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 244
Study 11950408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg preoperatively
Number of subjects: 61
Study 11950408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10559571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 12
Study 10559571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7722137 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 1012
Study 7722137 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 1012
Study 2039963 — intervention group
Group type: EXPERIMENTAL
Intervention: Telebrix 38 (2% solution in water)
Number of subjects: 55
Study 2039963 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin (2% solution in water)
Number of subjects: 55
Study 2039963 — intervention group
Group type: EXPERIMENTAL
Intervention: Telebrix 38
Number of subjects: 55
Study 2039963 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 55
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sulprostone
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraamniotic injections
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic injections following intramuscular injection for priming
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming administration
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: No effect noted
Number of subjects: 114
Study 7215768 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe vomiting
Number of subjects: 114
Study 31592954 — intervention group
Group type: EXPERIMENTAL
Intervention: LV rehabilitation (rehabilitation with a therapist)
Number of subjects: 255
Study 31592954 — intervention group
Group type: COMPARATOR
Intervention: Basic LV services (LV devices dispensed without therapy)
Number of subjects: 255
Study 28329346 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 8 mg/kg
Number of subjects: 12
Study 28329346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) 200 µg/kg
Number of subjects: 12
Study 28329346 — intervention group
Group type: COMPARATOR
Intervention: Both DEC and IVM
Number of subjects: 12
Study 26083950 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-TC (dendritic cells loaded with antigens from irradiated autologous tumor cells)
Number of subjects: 143
Study 26083950 — intervention group
Group type: COMPARATOR
Intervention: TC (irradiated tumor cells)
Number of subjects: 143
Study 26083950 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-TC (in patients with no evidence of disease at treatment start)
Number of subjects: 143
Study 26083950 — intervention group
Group type: COMPARATOR
Intervention: TC (in patients with no evidence of disease at treatment start)
Number of subjects: 143
Study 26083950 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-TC (in patients with detectable metastases)
Number of subjects: 143
Study 26083950 — intervention group
Group type: COMPARATOR
Intervention: TC (in patients with detectable metastases)
Number of subjects: 143
Study 24892331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy (ICBT)
Number of subjects: 81
Study 24892331 — intervention group
Group type: COMPARATOR
Intervention: Interstitial brachytherapy (IB)
Number of subjects: 81
Study 24892331 — intervention group
Group type: COMPARATOR
Intervention: Interstitial brachytherapy without tandem loading (IBWT)
Number of subjects: 81
Study 24892331 — intervention group
Group type: COMPARATOR
Intervention: Interstitial brachytherapy with tandem source loading (IBT)
Number of subjects: 81
Study 23173245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined Chinese materia medica for tonifying shen and soothing gan (CMMTSSG)
Number of subjects: 97
Study 23173245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined CMMTSSG
Number of subjects: 97
Study 23173245 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment
Number of subjects: 97
Study 20232047 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-TGI-high P(aw)
Number of subjects: 22
Study 20232047 — intervention group
Group type: COMPARATOR
Intervention: HFO-high P(aw)
Number of subjects: 22
Study 20232047 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-TGI-low P(aw)
Number of subjects: 22
Study 20232047 — intervention group
Group type: COMPARATOR
Intervention: HFO-low P(aw)
Number of subjects: 22
Study 17623225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (15 ml/day, 8.1 g ALA)
Number of subjects: 35
Study 17623225 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (15 ml/day, 11.2 g LA)
Number of subjects: 35
Study 17623225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Number of subjects: 35
Study 17623225 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 35
Study 15708217 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal mediation during presentation of novel figural designs
Number of subjects: 0
Study 15708217 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent verbal interference task during encoding
Number of subjects: 0
Study 15708217 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent visual interference task during encoding
Number of subjects: 0
Study 11873530 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (50% of all injuries)
Number of subjects: 339
Study 11873530 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (30% of injuries linked to running)
Number of subjects: 339
Study 11873530 — intervention group
Group type: COMPARATOR
Intervention: Illness (Control)
Number of subjects: 339
Study 11873530 — intervention group
Group type: EXPERIMENTAL
Intervention: Injuries (General)
Number of subjects: 339
Study 10546421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium lactate 12% lotion
Number of subjects: 43
Study 10546421 — intervention group
Group type: COMPARATOR
Intervention: Liposome-based moisturizing lotion
Number of subjects: 43
Study 8696435 — intervention group
Group type: EXPERIMENTAL
Intervention: Early range of motion exercises starting 3 days postoperatively
Number of subjects: 57
Study 8696435 — intervention group
Group type: COMPARATOR
Intervention: Late range of motion exercises starting 14 days postoperatively
Number of subjects: 57
Study 8696435 — intervention group
Group type: EXPERIMENTAL
Intervention: Early range of motion exercises
Number of subjects: 57
Study 2402206 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) diet
Number of subjects: 12
Study 2402206 — intervention group
Group type: COMPARATOR
Intervention: Low Carbohydrate (LC) diet
Number of subjects: 12
Study 2402206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HC and LC diets
Number of subjects: 12
Study 7051452 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg chloroquine base per kg body-weight (single dose)
Number of subjects: 239
Study 7051452 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg chloroquine base per kg body-weight (given over three days)
Number of subjects: 239
Study 7051452 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro sensitivity testing
Number of subjects: 239
Study 7051452 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate requiring higher concentration
Number of subjects: 239
Study 31109784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIE)
Number of subjects: 30
Study 31109784 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control trial (CON)
Number of subjects: 30
Study 29068863 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal breathing
Number of subjects: 13
Study 29068863 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing-in maneuver with normal breathing
Number of subjects: 13
Study 29068863 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing-in maneuver with Pilates breathing
Number of subjects: 13
Study 25378059 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of subcutaneous immunotherapy (IT3)
Number of subjects: 81
Study 25378059 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of subcutaneous immunotherapy (IT5)
Number of subjects: 81
Study 25378059 — intervention group
Group type: COMPARATOR
Intervention: Comparison between IT3 and IT5
Number of subjects: 81
Study 24988825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (started at 300 mg daily, increased to a maximum of 1800 mg)
Number of subjects: 0
Study 24988825 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (started at 250 mg daily, increased to a maximum of 1500 mg)
Number of subjects: 0
Study 23063888 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic condition
Number of subjects: 0
Study 23063888 — intervention group
Group type: COMPARATOR
Intervention: Perceptual condition
Number of subjects: 0
Study 19487623 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/5 mL) for 12 weeks, mean maximum dosage 16.5 mg/d (maximum 20 mg/d)
Number of subjects: 149
Study 19487623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 149
Study 19487623 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/5 mL) for 12 weeks
Number of subjects: 149
Study 19558735 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PEEP plus sigh breaths (twice the baseline tidal volume, plateau pressure < 40 cm H(2)O) every 25 breaths
Number of subjects: 12
Study 19558735 — intervention group
Group type: COMPARATOR
Intervention: Optimal PEEP alone
Number of subjects: 12
Study 19558735 — intervention group
Group type: COMPARATOR
Intervention: Optimal PEEP plus one sustained inflation (40 cm H(2)O for 30 s)
Number of subjects: 12
Study 15936996 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of pravastatin daily
Number of subjects: 4162
Study 15936996 — intervention group
Group type: COMPARATOR
Intervention: 80 mg of atorvastatin daily
Number of subjects: 4162
Study 12230139 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in a slightly annoyed mood
Number of subjects: 0
Study 12230139 — intervention group
Group type: COMPARATOR
Intervention: Participants in a neutral affective state
Number of subjects: 0
Study 12230139 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of current mood with noise sensitivity
Number of subjects: 0
Study 9597609 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 102
Study 9597609 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures
Number of subjects: 102
Study 8186061 — intervention group
Group type: EXPERIMENTAL
Intervention: Litoxetine 10 mg
Number of subjects: 12
Study 8186061 — intervention group
Group type: EXPERIMENTAL
Intervention: Litoxetine 25 mg
Number of subjects: 12
Study 8186061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2879175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 19
Study 2879175 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Mannitol
Number of subjects: 19
Study 12463779 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance measurement feedback on claims-based measures of care process
Number of subjects: 2158
Study 12463779 — intervention group
Group type: COMPARATOR
Intervention: Medical record-based measures
Number of subjects: 2158
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of statin, dual antiplatelet therapy, and beta-blockers prescribed to 79.6% of patients upon discharge.
Number of subjects: 357
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system inhibitor prescribed to 67.3% of patients with LVEF ≤40%.
Number of subjects: 357
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker prescribed to 91.8% of patients with LVEF ≤40%.
Number of subjects: 357
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment with statins in patients with prior history of CAD.
Number of subjects: 357
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment with antiplatelets in patients with prior history of CAD.
Number of subjects: 357
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment with beta-blockers in patients with prior history of CAD.
Number of subjects: 357
Study 31219734 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal LDL-C of <70 mg/dl at admission in CAD patients.
Number of subjects: 357
Study 29696317 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100
Study 29696317 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 100
Study 26920640 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog® KwikPen™ 200 units/mL (IL 200 pen)
Number of subjects: 106
Study 26920640 — intervention group
Group type: COMPARATOR
Intervention: Humalog KwikPen 100 units/mL (IL 100 pen)
Number of subjects: 106
Study 24929928 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD (n=31)
Number of subjects: 92
Study 24929928 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-coaching (EC) (n=31)
Number of subjects: 92
Study 24929928 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control (n=30)
Number of subjects: 92
Study 22705939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Movement Program (MMP) - 12 weekly sessions
Number of subjects: 49
Study 22705939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sessions)
Number of subjects: 49
Study 20402990 — intervention group
Group type: EXPERIMENTAL
Intervention: Two brief motivationally focused sessions (first during incarceration, second 1 month later after community re-entry)
Number of subjects: 245
Study 20402990 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (assessment-only condition)
Number of subjects: 245
Study 20402990 — intervention group
Group type: EXPERIMENTAL
Intervention: Two brief motivationally focused sessions
Number of subjects: 245
Study 18566199 — intervention group
Group type: EXPERIMENTAL
Intervention: WarmAir
Number of subjects: 184